Welcome to our dedicated page for Landos Biopharma news (Ticker: LABP), a resource for investors and traders seeking the latest updates and insights on Landos Biopharma stock.
Landos Biopharma, Inc. (LABP) is a clinical-stage biotechnology company pioneering oral therapies for autoimmune diseases through innovative immunometabolic research. This page provides centralized access to official news and developments surrounding LABP's scientific advancements, clinical trials, and corporate milestones.
Investors and stakeholders will find timely updates on LABP's lead investigational drug NX-13, including Phase 2 trial progress for ulcerative colitis treatment. The curated news archive features regulatory filings, partnership announcements, and financial reports essential for informed decision-making.
Our coverage spans key developments including clinical trial outcomes, research collaborations, and strategic corporate actions. All content is verified through primary sources to ensure accuracy in reporting scientific data and business developments.
Bookmark this page for direct access to LABP's latest advancements in inflammatory bowel disease research and emerging treatment paradigms. Check regularly for updates on novel oral therapies that aim to transform autoimmune disease management.
Landos Biopharma announced FDA clearance for its IND application for LABP-104, a promising treatment for rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). This marks the seventh IND approval for the company, showcasing progress in its pipeline. A Phase 1 trial has been initiated with topline results expected in the first half of 2022. LABP-104 employs a novel mechanism that reduces inflammation with potentially fewer side effects compared to existing therapies. The ongoing trial aims to evaluate the safety and pharmacokinetics of this innovative candidate.
Landos Biopharma (LABP) announced the initiation of a Phase 1 trial for LABP-104, a small-molecule LANCL2 agonist aimed at treating systemic lupus erythematosus (SLE). The study will enroll 56 healthy volunteers to evaluate the drug's safety, tolerability, and pharmacokinetics. LABP-104 is linked to a 15-gene signature developed using Landos' LANCE® A.I. platform, which could help identify patients most likely to benefit from treatment. Topline results are expected in the first half of 2022, addressing a critical unmet need in SLE therapeutics for approximately 1.5 million patients in the U.S.
Landos Biopharma (NASDAQ: LABP) announced FDA clearance for its Investigational New Drug (IND) application for LABP-104, aimed at treating systemic lupus erythematosus (SLE). This marks the company’s sixth IND approval in under four years. The Phase 1 trial is set to begin before year-end, with topline results expected in the first half of 2022. LABP-104 activates the LANCL2 pathway, showing promising efficacy in preclinical studies. Given the high unmet need for alternative therapies in SLE, LABP-104 represents a potential frontline oral option for about 1.5 million patients in the US.
Landos Biopharma (NASDAQ: LABP) has published a peer-reviewed article in Scientific Reports, showcasing the efficacy of omilancor in treating psoriasis. The study revealed a 60% reduction in the psoriasis area and severity index (PASI) score and significant decreases in inflammation. Omilancor, targeting the LANCL2 pathway, shows promise as a non-steroidal treatment for psoriasis while currently being developed for ulcerative colitis, Crohn’s disease, and eosinophilic esophagitis. This publication enhances the therapeutic potential of the LANCE A.I. platform and broadens Landos' inflammation pipeline.
Landos Biopharma (NASDAQ: LABP) announced that CEO Josep Bassaganya-Riera will participate in the Truist Securities CEO Fireside Chat Series on September 30, 2021. The event will feature a discussion led by Dr. Robyn Karnauskas, focusing on Landos' innovative work in developing therapeutics for autoimmune diseases using its LANCE® A.I. platform. Landos has 17 programs targeting various conditions, including ulcerative colitis and Crohn's disease, and plans to initiate Phase 1 studies in eosinophilic esophagitis in 2022.
Landos Biopharma (NASDAQ: LABP) has announced a collaboration with the Icahn School of Medicine at Mount Sinai to conduct a Phase 2 trial of omilancor in patients with moderate-to-severe Crohn’s disease (CD). Funded by a $3 million NIH grant, the trial will compare omilancor with adalimumab over 12 weeks in approximately 40 patients. The study aims to evaluate the drug's efficacy and safety while providing insights into its action on regulatory T cells in the gastrointestinal tract. Omilancor is developed using Landos’ LANCE® Advanced A.I. platform and addresses the unmet need for safer oral therapies in CD.
Landos Biopharma (NASDAQ: LABP) announced promising preclinical results for LABP-104, an oral LANCL2 agonist for Systemic Lupus Erythematosus (SLE). The findings, to be presented at the ACR Convergence 2021, indicate enhanced Treg function, reduced kidney inflammation, and decreased interferon gamma signaling. LABP-104 showed protection against worsening proteinuria in over 90% of tested mice. The company anticipates Phase 1 clinical trials to commence in Q4 2021, expanding its pipeline in autoimmune disease treatments.
Landos Biopharma (NASDAQ: LABP) announced that its Chairman, President, and CEO, Josep Bassaganya-Riera, will attend two investor conferences in September 2021. The Citi’s 16th Annual BioPharma Conference is scheduled for September 8-10, featuring 1x1 meetings, while the H.C. Wainwright 23rd Annual Global Investment Conference will take place on September 13, 2021, with an on-demand presentation available from 7:00 a.m. ET. Landos is known for its LANCE A.I. platform, focusing on innovative therapies for autoimmune diseases, including its lead asset omilancor.
Landos Biopharma (NASDAQ: LABP) has announced a research collaboration with Dr. Peter Calabresi from Johns Hopkins University, funded by the NIH, to validate the NLRX1 immunometabolic pathway in Multiple Sclerosis (MS). The company aims to develop LABP-66, an oral therapy targeting this pathway, potentially improving treatment for MS and Alzheimer's Disease. The MS drug market is projected to grow from $18.6 billion in 2021 to $26.6 billion by 2028. Landos anticipates filing for IND for LABP-66 in 2022, alongside other development programs targeting various autoimmune conditions.
Landos Biopharma (NASDAQ: LABP) will participate in several investor events in August 2021. Key events include the BTIG Virtual Biotechnology Conference on August 9-10, Canaccord Genuity 41st Annual Growth Conference from August 10-12, and the BMO BioPharma Spotlight Series on August 12. Presentations will be made on August 10 at 3 PM EDT, August 11 at 10:30 AM ET, and August 12 at 10:50 AM ET, with an in-person segment on August 12 at Topping Rose House, Bridgehampton, NY. Investors can contact the company for meetings and access presentations via their website.
